MedTrace Logo

The Role of Central Sensitization on Biopsychosocial Factors in Primary Sjögren's Syndrome

NCT06410742 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-02-28

No results posted yet for this study

Summary

Following the guidance of individuals with primary Sjögren's Syndrome who receive diagnosis, routine medical care, and treatment management, the evaluations will be performed once by the researchers and will take approximately one hour.

In addition, healthy individuals with a similar average age to the evaluation group without any disease diagnosis will be included in the study as a control group. Evaluations of the healthy group will be made once by the researchers and will take approximately one hour.

Data will be collected face to face at the Faculty of Physical Therapy and Rehabilitation, Rheumatology Unit.

Data collection tool of the research:

* Information about patients will be recorded with the Demographic Information Form.
* EULAR Sjögren's Syndrome Disease Activity Index
* EULAR Sjögren's Syndrome Patient Reporting Index
* Primary Sjögren's Syndrome Quality of Life Scale
* BETY-Biopsychosocial Questionnaire
* Central Sensitization Scale
* Pain Catastrophizing Scale
* Hospital Anxiety and Depression Scale
* Multidimensional Fatigue Rating Scale
* Turkish Eating Assessment Tool
* Yale Swallow Protocol
* Test of Mastication and Swallowing Solids
* Dysphagia Limit Test
* Xerostomia inventory

Conditions

  • Sjogren's Syndrome

Sponsors & Collaborators

  • Kahramanmaras Sutcu Imam University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-19
Primary Completion
2024-12-30
Completion
2025-01-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06410742 on ClinicalTrials.gov